The tested enterococcal species isolates (1,017) were used to identify resistance (R) mechanisms and possible virulence genes. The strains were predominantly from bacteremias although isolates varying from 291 (Mountain) to 390 (East South Central) were used to identify resistance (R) mechanisms and possible virulence genes.

The strains were predominantly from bacteremias although isolates varying from 291 (Mountain) to 390 (East South Central) were used to identify resistance (R) mechanisms and possible virulence genes.

50% 90% Range Susceptible/Resistant 50% 90% Range Susceptible/Resistant

- Penicillin
- Oxacillin
- Erythromycin
- Gentamicin
- Vancomycin
- Ciprofloxacin
- Quinupristin/dalfopristin
- Ceftriaxone
- Linezolid

- Linezolid activity compared to 9 other agents when tested in the LEADER Program (USA, 2009), 6,414 strains.

**RESULTS**

- Enterococci (1,017) Linezolid 1 1
- -haem. streptococci (1,521) NT NT 0.00 0.00 0.00 0.00
- CoNS (4,526) 0.20 1.13 1.61 1.76 1.64 1.47
- S. pneumoniae 0.03 0.03 0.03 0.06 0.10 0.15
- S. aureus 0.03 0.06 0.06 0.12 0.18 0.24
- Enterococci (1,017) 0.0 0.1 4.0 53.4 98.9 99.2 99.6 100.0

**AMENDED ABSTRACT**

**INTRODUCTION**

Linezolid experience and accurate determination of resistance (LEADER) Program: United States (USA) Results for 2009

**LLZMand ABSTRACT**

**CLINICAL AND LABORATORY STANDARDS INSTITUTE**

**REFERENCES**

**CONCLUSIONS**

The LEADER surveillance program has monitored linezolid (LLZ) resistance and activity against Gram-positive pathogens since 2003. The LEADER program has now sampled 33,378 strains over six surveillance years using reference CLSI methods to identify resistance and spectrum analysis of linezolid using clinical isolates from 16 LEADER surveillance sites.

**DISCUSSION**

The LEADER surveillance program has monitored linezolid (LLZ) resistance and activity against Gram-positive pathogens since 2003. The LEADER program has now sampled 33,378 strains over six surveillance years using reference CLSI methods to identify resistance and spectrum analysis of linezolid using clinical isolates from 16 LEADER surveillance sites.

The LEADER surveillance program has monitored linezolid (LLZ) resistance and activity against Gram-positive pathogens since 2003. The LEADER program has now sampled 33,378 strains over six surveillance years using reference CLSI methods to identify resistance and spectrum analysis of linezolid using clinical isolates from 16 LEADER surveillance sites.

**REFERENCES**

The LEADER surveillance program has monitored linezolid (LLZ) resistance and activity against Gram-positive pathogens since 2003. The LEADER program has now sampled 33,378 strains over six surveillance years using reference CLSI methods to identify resistance and spectrum analysis of linezolid using clinical isolates from 16 LEADER surveillance sites.